Evidence indicates that achieving pCR through neoadjuvant chemotherapy combined with Trastuzumab in patients with HER2-positive breast cancer correlates with improved disease-free survival (DFS) and overall survival (OS) outcomes relative to patients who do not attain pCR [9,10,11,12]. Here, ERBB2 is linked to breast carcinoma.